Gene therapy plus Keytruda for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach, gastroesophageal junction, or esophageal cancer that can be injected into with a needle, with a tumor at least 1 cm in size.
- Your tumor must have been tested for PD-L1 (a protein affecting immune response), and your doctor should know your score.
- If your PD-L1 score is above 1: you must have already tried at least one line of standard treatment that included an immunotherapy drug (a PD-1 or PD-L1 inhibitor), and your cancer must have progressed during or within 3 months of finishing that treatment.
- If your PD-L1 score is below 1: you must NOT have had prior immunotherapy, but you must have received at least one line of chemotherapy or other standard therapy for advanced disease.
- You cannot have an active autoimmune disease that needed strong immune-suppressing drugs in the last 2 years, cannot be on high-dose steroids (more than 20 mg prednisone daily) within the last week, and cannot have had severe immune side effects from prior immunotherapy.
- No active brain metastases, no uncontrolled infections, no HIV/hepatitis B or C, no other progressing cancer within 3 years, and no organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (pembrolizumab, also known as Keytruda) with chemotherapy or chemoradiotherapy for people in India with certain advanced cancers of the stomach, bile ducts, or cervix. The goal is to see if adding immunotherapy helps control the cancer better than standard treatment alone.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This trial tests a new drug (ONO-4578) combined with the usual immunotherapy (nivolumab) and chemotherapy for stomach cancer that has not been treated before. It aims to see if adding this drug helps shrink tumors or slows disease growth better than placebo.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.